labeling-changes
1 cases — ← All topics
| Case | Title | Lower Court | Docketed | Status | Flags | Tags | Question Presented |
|---|---|---|---|---|---|---|---|
| 18-803 | Wendy B. Dolin v. GlaxoSmithKline, LLC, fka SmithKline Beecham Corporation | Seventh Circuit | 2018-12-21 | Denied | Relisted (2) | clinical-trials drug-labeling drug-manufacturer fda-regulations impossibility-preemption labeling-changes preemption truthful-risks unilateral-labeling-changes unilateral-warning wyeth-v-levine | Does federal law prevent a drug manufacturer from enhancing its label to reflect truthful risks revealed in its clinical trials when the relevant FDA … |